In an interview with Pharmalot, former FDA associate chief counsel Arnie Friede discusses the impact of last month’s $181 million Risperdal settlement on pharmaceuticals’ abilities to distribute journal articles that contain off-label information.
Support MIA
MIA relies on the support of its readers to exist. Please consider a donation to help us provide news, essays, podcasts and continuing education courses that explore alternatives to the current paradigm of psychiatric care. Your tax-deductible donation will help build a community devoted to creating such change.